These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 8975923)

  • 1. Cryptococcus neoformans and cryptococcal glucuronoxylomannan, galactoxylomannan, and mannoprotein induce different levels of tumor necrosis factor alpha in human peripheral blood mononuclear cells.
    Chaka W; Verheul AF; Vaishnav VV; Cherniak R; Scharringa J; Verhoef J; Snippe H; Hoepelman IM
    Infect Immun; 1997 Jan; 65(1):272-8. PubMed ID: 8975923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor necrosis factor-inducing activities of Cryptococcus neoformans components.
    Delfino D; Cianci L; Migliardo M; Mancuso G; Cusumano V; Corradini C; Teti G
    Infect Immun; 1996 Dec; 64(12):5199-204. PubMed ID: 8945566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of TNF-alpha in human peripheral blood mononuclear cells by the mannoprotein of Cryptococcus neoformans involves human mannose binding protein.
    Chaka W; Verheul AF; Vaishnav VV; Cherniak R; Scharringa J; Verhoef J; Snippe H; Hoepelman AI
    J Immunol; 1997 Sep; 159(6):2979-85. PubMed ID: 9300722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toll-like receptor 4 mediates intracellular signaling without TNF-alpha release in response to Cryptococcus neoformans polysaccharide capsule.
    Shoham S; Huang C; Chen JM; Golenbock DT; Levitz SM
    J Immunol; 2001 Apr; 166(7):4620-6. PubMed ID: 11254720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An anti-Cryptococcus neoformans monoclonal antibody directed against galactoxylomannan.
    van de Moer A; Salhi SL; Cherniak R; Pau B; Garrigues ML; Bastide JM
    Res Immunol; 1990 Jan; 141(1):33-42. PubMed ID: 2189167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucuronoxylomannan, galactoxylomannan, and mannoprotein occupy spatially separate and discrete regions in the capsule of Cryptococcus neoformans.
    Jesus MD; Nicola AM; Chow SK; Lee IR; Nong S; Specht CA; Levitz SM; Casadevall A
    Virulence; 2010; 1(6):500-8. PubMed ID: 21178496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cryptococcus neoformans and its cell wall components induce similar cytokine profiles in human peripheral blood mononuclear cells despite differences in structure.
    Walenkamp AM; Chaka WS; Verheul AF; Vaishnav VV; Cherniak R; Coenjaerts FE; Hoepelman IM
    FEMS Immunol Med Microbiol; 1999 Dec; 26(3-4):309-18. PubMed ID: 10575143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Capsular polysaccharides galactoxylomannan and glucuronoxylomannan from Cryptococcus neoformans induce macrophage apoptosis mediated by Fas ligand.
    Villena SN; Pinheiro RO; Pinheiro CS; Nunes MP; Takiya CM; DosReis GA; Previato JO; Mendonça-Previato L; Freire-de-Lima CG
    Cell Microbiol; 2008 Jun; 10(6):1274-85. PubMed ID: 18284419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of interleukin-6 mRNA in rat alveolar macrophages by in vitro exposure to both Cryptococcus neoformans and anti-C. neoformans antiserum.
    Li RK; Mitchell TG
    J Med Vet Mycol; 1997; 35(5):327-34. PubMed ID: 9402525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cryptococcal polysaccharides induce L-selectin shedding and tumor necrosis factor receptor loss from the surface of human neutrophils.
    Dong ZM; Murphy JW
    J Clin Invest; 1996 Feb; 97(3):689-98. PubMed ID: 8609224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunoregulation by capsular components of Cryptococcus neoformans.
    Vecchiarelli A
    Med Mycol; 2000 Dec; 38(6):407-17. PubMed ID: 11204878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Receptor-mediated recognition of Cryptococcus neoformans.
    Levitz SM
    Nihon Ishinkin Gakkai Zasshi; 2002; 43(3):133-6. PubMed ID: 12145626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Cryptococcus neoformans galactoxylomannan-protein conjugate as vaccine candidate against murine cryptococcosis.
    Chow SK; Casadevall A
    Vaccine; 2011 Feb; 29(10):1891-8. PubMed ID: 21238568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Capsular localization of the Cryptococcus neoformans polysaccharide component galactoxylomannan.
    De Jesus M; Nicola AM; Rodrigues ML; Janbon G; Casadevall A
    Eukaryot Cell; 2009 Jan; 8(1):96-103. PubMed ID: 18952901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the capsular polysaccharides of Cryptococcus neoformans on phagocyte migration and inflammatory mediators.
    Ellerbroek PM; Walenkamp AM; Hoepelman AI; Coenjaerts FE
    Curr Med Chem; 2004 Jan; 11(2):253-66. PubMed ID: 14754421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms for induction of L-selectin loss from T lymphocytes by a cryptococcal polysaccharide, glucuronoxylomannan.
    Dong ZM; Jackson L; Murphy JW
    Infect Immun; 1999 Jan; 67(1):220-9. PubMed ID: 9864219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enzyme immunoassay detection of IgM to galactoxylomannan of Cryptococcus neoformans.
    Reiss E; Cherniak R; Eby R; Kaufman L
    Diagn Immunol; 1984; 2(2):109-15. PubMed ID: 6388977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aggregation of Cryptococcus neoformans by surfactant protein D is inhibited by its capsular component glucuronoxylomannan.
    van de Wetering JK; Coenjaerts FE; Vaandrager AB; van Golde LM; Batenburg JJ
    Infect Immun; 2004 Jan; 72(1):145-53. PubMed ID: 14688091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Production of tumor necrosis factor alpha in human leukocytes stimulated by Cryptococcus neoformans.
    Levitz SM; Tabuni A; Kornfeld H; Reardon CC; Golenbock DT
    Infect Immun; 1994 May; 62(5):1975-81. PubMed ID: 8168965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mannoproteins of Cryptococcus neoformans induce proliferative response in human peripheral blood mononuclear cells (PBMC) and enhance HIV-1 replication.
    Orendi JM; Verheul AF; De Vos NM; Visser MR; Snippe H; Cherniak R; Vaishnav VV; Rijkers GT; Verhoef J
    Clin Exp Immunol; 1997 Feb; 107(2):293-9. PubMed ID: 9030866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.